证券代码：002286 证券简称：保龄宝 公告编号：2026-010 渤海证券于2026年3月3日通过大宗交易方式强制平仓永裕投资持有的保龄 宝股票4,679,600股，占公司总股本的1.23%。具体内容详见公司于2026年3月5日 披露的《关于控股股东部分股份被司法强制执行的进展暨触及1%刻度的公告》 （公告编号：2026-009）。 2026年3月19日，永裕投资收到渤海证券《司法扣划执行完毕通知书》。渤 海证券近期通过大宗交易方式及集中竞价方式司法协助执行永裕投资持有的保 龄宝股票3,457,700股，占公司总股本的0.91%。司法执行金额为3,200万元（扣 除手续费和相关税费），已经划转至黑龙江省哈尔滨市中级人民法院执行专户。 本次司法处置部分已执行完毕。 保龄宝生物股份有限公司 关于控股股东部分股份被司法强制执行完成的公告 公司控股股东北京永裕投资管理有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 近期，渤海证券股份有限公司（以下简称"渤海证券"）收到黑龙江省哈尔 滨市中级人民法院《协助 ...

证券代码：002286 证券简称：保龄宝 公告编号：2026-009 保龄宝生物股份有限公司关于 控股股东部分股份被司法强制执行的进展 暨触及1%刻度的公告 公司控股股东北京永裕投资管理有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、控股股东部分股份被司法强制执行的进展情况 2026年3月4日，公司收到渤海证券出具的成交记录凭证，渤海证券于2026 年3月3日通过大宗交易方式强制平仓永裕投资持有的保龄宝股票4,679,600股， 占公司总股本的1.23%，强制平仓金额45,532,508元。永裕投资及其一致行动人 深圳松径投资合伙企业（有限合伙）（以下简称"松径投资"）、国投证券国 际金融控股有限公司-2号投资计划（以下简称"2号投资计划"）合计持有公司 股份的比例由17.20%减少至15.97%，权益变动触及1%刻度。 截至本公告披露日，渤海证券强制平仓部分已实施完成，未超过减持额度 限制。因诉讼司法处置部分目前暂未实施，本次司法强制执行尚未实施完毕。 二、本次强制平仓触及 1%刻度的情况 1 ...

Group 1 - The core viewpoint of the article highlights a short-term surge in A-share sugar substitute concept stocks, with Baolingbao hitting the daily limit, and companies like Sanyuan Bio, Jinhui Industrial, and Huakang Co. also experiencing gains [1] Group 2 - Baolingbao reached the daily limit, indicating strong investor interest and confidence in the sugar substitute sector [1] - Sanyuan Bio, Jinhui Industrial, and Huakang Co. followed suit with notable increases in their stock prices, reflecting a broader trend in the market [1]

Core Viewpoint - The company Baolingbao (002286.SZ) has received a notification from Songjing Investment regarding the completion of its shareholding increase plan, which has resulted in a significant increase in the company's total shareholding by the investment entities involved [1] Group 1: Shareholding Increase Details - From February 12 to February 13, 2026, the 2nd investment plan increased its holdings by 3.75 million shares, representing 0.99% of the company's total share capital, raising the combined shareholding of Songjing Investment and its concerted party, Beijing Yongyu Investment Management Co., Ltd., from 15.00% to 15.99% [1] - On February 24, 2026, the 2nd investment plan further increased its holdings by 3.5 million shares, accounting for 0.92% of the total share capital, bringing the combined shareholding to 16.91% [1] - On February 25, 2026, an additional 1.12 million shares were acquired, which is 0.29% of the total share capital, resulting in a total shareholding of 17.20% for the investment entities [1] Group 2: Overall Shareholding Increase - Since the start of the shareholding increase plan on October 8, 2024, Songjing Investment and the 2nd investment plan have collectively acquired 18.566 million shares, which is 4.88% of the company's existing total share capital [1]

Core Viewpoint - The actual controller of Baolingbao, Dai Sichong, through Songjing Investment and its concerted action party, plans to increase its shareholding in the company by acquiring 18.5664 million shares, representing 4.88% of the total share capital, with an investment of RMB 190 million, raising its stake from 15.00% to 17.20% [1] Summary by Category - **Shareholding Increase** - The shareholding increase will occur from October 8, 2024, to February 25, 2026, through centralized bidding [1] - The total number of shares to be acquired is 18.5664 million [1] - **Financial Commitment** - The total expenditure for this share acquisition is RMB 190 million [1] - **Ownership Change** - Following the completion of the share acquisition plan, the ownership percentage will rise from 15.00% to 17.20% [1]

保龄宝生物股份有限公司 关于实际控制人控制的企业增持股份触及1%刻度 暨增持计划实施完成的公告 证券代码：002286 证券简称：保龄宝 公告编号：2026-008 股东深圳松径投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 自本次增持计划开始之日（2024年10月8日）起至2026年2月25日，本次增持 主体松径投资、2号投资计划合计增持公司股票18,566,356股，占公司现有总股本 的比例4.88%，本次增持计划实施完成。现将具体情况公告如下： 二、本次增持股份触及1%刻度的情况 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、本次增持计划的基本情况 保龄宝生物股份有限公司（以下简称"公司""保龄宝"）实际控制人之一戴斯 聪先生控制的企业深圳松径投资合伙企业（有限合伙）（以下简称"松径投资"） 原计划于2024年10月8日起6个月内，通过深圳证券交易所系统允许的方式（包括 但不限于集中竞价、大宗交易等）增持公司股份，拟增持股份数不低于18,488,369 股(占公司当时总股本的5%)，不超过36,976,738股(占公司 ...

Group 1 - The core point of the article is that Baolingbao (002286) reported a total of 32,445 shareholders as of February 13, 2026 [1]

Group 1 - The company Baolingbao reported that as of February 10, 2026, the total number of shareholders is 32,799 [2]

Group 1 - The company Baolingbao reported that as of February 10, 2026, the total number of shareholders is 32,799 [2]

Investment Rating - The industry rating is "Overweight" [3] Core Insights - The report highlights the ongoing active research in life sciences and the rapid integration of biotechnology into economic and social development, providing innovative solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [3][4]. Industry Performance - The Huazhong Synthetic Biology Index increased by 0.11% to 1278.44 during the week of February 2-6, 2026, outperforming the Shanghai Composite Index by 1.39 percentage points and the ChiNext Index by 3.40 percentage points [4]. - The report notes that the synthetic biology sector is experiencing a policy dividend, with Shenzhen proposing up to 100 million yuan in support for R&D efforts in the field [8]. Company Developments - Beijing Huaguan Bio completed a multi-hundred million yuan C-round financing to enhance its R&D and production capabilities in the pharmaceutical and health sectors [32]. - Dejin Bio secured several million yuan in A-round financing to advance its recombinant botulinum toxin clinical research and international expansion [33]. - The report mentions that Impossible Foods is leveraging technology to reshape the plant protein market [11]. Market Dynamics - The report indicates that the synthetic biology sector is witnessing a surge in financing, with nearly a hundred companies completing new funding rounds since 2025 [31]. - The top five companies in the synthetic biology sector by stock performance during the week were Pingtan Development (+12%), Jinbo Bio (+12%), Huaxi Bio (+12%), Shandong Heda (+10%), and Yaxiang Co. (+10%) [17]. Policy and Regulatory Developments - The Ministry of Industry and Information Technology announced 35 examples of non-grain bio-based materials, marking a significant step towards establishing a new green development framework [7]. - The National Health Commission approved 22 new food items, including a significant breakthrough in domestic human milk oligosaccharides (HMOs) production [7]. Research and Innovation - Tsinghua University has initiated a national key R&D project focused on the intelligent design principles of efficient microbial chassis cells, aiming for breakthroughs in both fundamental theory and application demonstration [9]. - The report highlights the strategic cooperation between Tianjin University and China National Petroleum Corporation to expand efforts in synthetic biology and related fields [9].